To Study the Potential role of drug Hyrdoxyurea in Thalassemia in reducing the burden of frequent blood transfusion in children of Southern Rajasthan

To Study the role of Hydroxyurea in Transfusion Dependent Beta Thalassemia Major in children aged Less than 18 years in Southern Rajasthan - A Pre Post Interventional Study - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/071925

Enrollment

Registered

2024-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D561- Beta thalassemia

Interventions

Intervention1: Hydroxyurea: Capsule Hydroxyurea 20Mg/kg/Day once daily for a period of 6 Months with concurrent Folic acid, Calcium supplements.Patient will be advised to take Capsule Hydroxyurea Empt

Eligibility

Inclusion criteria

Inclusion criteria: All Known case of Beta Thallasemia Major less than 18 years of age visiting Thalassemia Day Care Centre for regular Blood Transfusion/Followup

Exclusion criteria

Exclusion criteria: Children having other causes of Anemia,Pre- exisitng Renal disease ,Pre- existing hepatic disease, Thromboctyopenia, Neutropenia, children having Chronic hepatitis B,C HIV ,HBsAg seropositivity,Not giving Informed consent were excluded from this study

Design outcomes

Primary

Measure	Time frame
To study the Efficacy of Hydroxyurea on Reduction of Need for frequent Blood Transfusion Requirements in children of Beta thalassemia MajorTimepoint: 6 MONTHS	—

Secondary

Measure	Time frame
To study the effect of Hydroxyurea in reduction of serum Ferritin Levels and overall burden of need for frequent Blood transfusionTimepoint: 6 MONTHS	—

Countries

India

Contacts

Public ContactDr Mohammad Asif

R.N.T Medical college

rntianasif@gmail.com9785056044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026